Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)

Bacharach J., Brubaker J.W., Evans D.G., LU F., Odani-Kawabata N., Yamabe T., Wirta D.L.

2024
American Journal of Ophthalmology

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

From the North Bay Eye Associates (J.B.), Petaluma, CA, United States; Sacramento Eye Consultants (J.W.B.), Sacramento, CA, United States; Total Eye Care, P.A.(D.G.E.), Memphis, TN, United States; Santen, Inc.(F.L., T.Y.), Emeryville, CA, United States; Santen Pharmaceutical Co., Ltd (N.O.-K., T.Y.), Osaka, Japan; Eye Research Foundation (D.L.W.), Newport Beach, CA, United States

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.

Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

View all Glaucoma publications